Erbitux
NHS failed to use extra cancer drug funds
June 17, 2011Sales and Marketing Cancer, Cancer Drugs Fund, Erbitux, avastin
The million pound fund set up to increase NHS uptake of new cancer drugs was widely underused, with just over …
Erbitux meets gold standard in rectal cancer
June 7, 2011Research and Development, Sales and Marketing Erbitux, Merck Serono, rectal cancer
Studies of Merck Serono’s Erbitux in rectal cancer have shown improved overall survival, a gold standard measure in oncology trials. …
Merck re-submits Erbitux to the EMA for lung cancer
March 30, 2011Sales and Marketing EGFR, Erbitux, Iressa, Merck KGaA, NSCLC, Tarceva, lung cancer drugs, non-small cell lung cancer
Merck KGaA has re-submitted Erbitux’s lung cancer licence extension to the EMA after its first application to the regulator was …
Erbitux ‘now standard of care’ in KRAS patients
June 3, 2010Sales and Marketing Erbitux, Merck Serono
A new survey suggests Merck Serono’s Erbitux has become a standard of care for KRAS wild-type metastatic colorectal cancer The …
Merck KGaA posts modest revenue increase
February 24, 20102009 financials, Erbitux, Merck KGaA, Merck Serono, Rebif
German pharma company Merck has posted a modest rise in revenue amidst strong pharma growth. Revenues increased 2.1% to 7.7 …
Merck Serono asks EMEA to re-think Erbitux rejection
July 30, 2009Research and Development, Sales and Marketing Cancer, EMEA, Erbitux, Europe, Merck Serono
Merck Serono is to appeal against the European rejection of Erbitux as a lung cancer treatment.Erbitux has been rejected as …
NICE approves Erbitux for colon cancer
June 1, 2009Research and Development, Sales and Marketing Erbitux, NICE
NICE has approved Merck Serono's Erbitux, making it a first-line therapy for many patients with a certain type of metastatic …
Merck Serono seeks first-line use for Erbitux
September 6, 2007Sales and Marketing Erbitux
Merck Serono has seeking a broader licence for its cancer drug Erbitux in Europe to include use as a first-line …
Latest content
FibroFind appoints Lee Borthwick as CEO
